Quantcast

Latest Cervarix Stories

6e8087ca2fa74af25c67a2e9cdf725961
2009-08-19 12:38:06

Researchers have found that the popular and highly advertised cervical cancer vaccine Gardasil has a low rate of side effects, but 32 deaths and questionable promotion strategies by its maker Merck & Co. has raised some concern.  Two separate studies were performed and submitted to the federal government's Vaccine Adverse Event Reporting System on girls and young women who were vaccinated with Gardasil from June 2006 through December 2008. The study found that the vaccine was known...

27fdacf7cef9734d090fa2c825da2d551
2009-07-09 11:40:00

The World Health Organization (WHO) has now approved a new cervical cancer vaccine from pharmaceutical company GlaxoSmithKline (GSK), which means that U.N. agencies and partners can now officially buy millions of doses of the vaccine for poor countries worldwide. GSK stated Thursday that the approval would help expedite the accessibility of Cervarix globally. Gardasil, the rival vaccine made by pharmaceutical company Merck & Co., was the first cervical cancer vaccine to be approved by...

2009-07-07 07:00:00

LONDON, July 7 /PRNewswire/ -- The final analysis of the largest efficacy trial of a cervical cancer vaccine is published today in The Lancet. The study, involving 18,644 women, confirmed GlaxoSmithKline's Cervarix(R) is highly effective at protecting against the two most common cervical cancer-causing human papillomavirus (HPV) types, 16 and 18. The study also showed that the vaccine provides cross-protection against HPV types 31, 33 and 45, the three most common cancer-causing virus types...

2009-07-01 16:12:07

Even under favorable assumptions, including lifelong protection against 70% of all cervical cancers and no side effects, vaccination against the human papillomavirus (HPV) is not cost-effective in the Netherlands, according to a study published online July 1 in the Journal of the National Cancer Institute.Researchers conducted the study because the cost effectiveness of HPV vaccination may be limited by the low number of cervical cancer cases and deaths in the region associated with the...

2009-06-08 08:01:31

 The HPV vaccine isn't just for teens. New research shows women ages 24 to 45 not already infected with the common sexually transmitted disease can receive protection against the virus following vaccination.Adolescent girls and young women have been the targets for HPV vaccination efforts. However, a rising age at first marriage, divorce and changing sexual habits has resulted in an increase in rates of HPV infection among women over the age of 24. Results of a new study show it's not...

2009-06-02 11:33:55

 Informing men that a new vaccine to prevent human papillomavirus (HPV) would also help protect their female partners against developing cervical cancer from the sexually transmitted infection did not increase their interest in getting the vaccine, according to a new Florida State University study.Mary Gerend, assistant professor of medical humanities and social sciences at the FSU College of Medicine, and Jessica Barley, a 2008 Florida State psychology graduate who based her honors...

2009-03-30 08:14:00

- GlaxoSmithKline submits final study data to FDA for cervical cancer vaccine PHILADELPHIA and LONDON, March 30 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) today provided the following update regarding its application to the U.S. Food and Drug Administration (FDA) for approval of CERVARIX(R), its vaccine to prevent cervical cancer and cervical pre-cancer related to human papillomavirus types 16 and 18. GSK has submitted final data from its Phase III pivotal efficacy study,...

2009-03-11 00:13:04

Most women are willing to be vaccinated against the human papillomavirus and have their daughters and sons vaccinated, as well, U.S. researchers say. The study, published in the journal Gynecologic Oncology, also found that Latino women are just as likely, if not more so, to accept HPV vaccine as non-Latinos. Since the incidence and mortality of cervical cancer are higher among Latino women in the United States, we were interested in whether the vaccine acceptance rate in this high-risk...

3bfdbc1ca3023313201f07224ad8ae7a1
2009-02-18 10:40:00

First state-level data show high acceptance rate of controversial vaccine Less than two years after the HPV vaccine was approved as a routine vaccination for girls aged 11 and older, one-quarter of California adolescent girls have started the series of shots that protect against human papillomavirus, which is strongly linked to cervical cancer. Additionally, a majority of teen girls, parents and young women in California say they would like to have the vaccine, according to a new policy brief...

2009-02-16 23:55:50

The human papillomavirus vaccine has not increased risks of Guillain-Barre but it warrants monitoring, U.S. researchers said. Thirty-six cases of Guillain-Barre syndrome -- a muscle disorder caused by the immune system attacking the peripheral nervous system -- have occurred after HPV vaccination. The vaccine has been in use since June 2006 after being approved by the U.S. government for use in girls ages 9-26 to protect against some types of HPV that can cause cervical cancer. Using data...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'